Cipla gets CDSCO nod to launch inhalation insulin
Cipla on Wednesday said it has received the nod from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza — inhalation human insulin in India.
Afrezza is a rapid-acting insulin delivered through an inhaler as compared to current insulins which are given as injections. Taken at the beginning of a meal, Afrezza dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream.
Cipla said Afrezza starts working in as early as 12 minutes and helps in reducing the rapid increase seen in sugar levels with meals. The effect of Afrezza lasts for about 2-3 hours and it closely resembles the body’s own response to insulin.
Afrezza, is developed and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus.
Cipla said it will make this drug accessible to all and empower millions to take control of their health with greater ease.
Entrepreneurship
Building Your Winning Startup Team: Key Strategies for Success
By — Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience
Entrepreneurship
Startup Fundraising: Essential Tactics for Securing Capital
By — Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience
Data Analysis
Animated Visualizations with Flourish Studio: Beginner to Pro
By — Prince Patni, Software Developer (BI, Data Science)
Artificial Intelligence(AI)
Java Programming with ChatGPT: Learn using Generative AI
By — Metla Sudha
